ER、EGFR在分化型甲状腺癌中的表达及其临床意义

目的:探讨雌激素受体(ER)和表皮生长因子受体(EGFR)在分化型甲状腺癌(DTC)中的表达及其意义.方法:用免疫组化SP法检测45例(DTC)组织中ER和EGFR的表达.结果:ER在DTC组中的阳性率为37.3％,明显高于良性腺瘤和正常组(P＜0.05);EGFR在DTC组中的阳性率为57.7％,明显高于两对照组(P＜0.05).ER在DTC中的表达与性别和年龄有关;EGFR的表达与DTC中的淋巴结转移有关.结论:ER和EGFR的表达可以作为鉴别甲状腺肿瘤良恶性的指标EGFR可作为甲状腺癌患者预后的指标.     

表皮生长因子家族及其在海胆中的研究进展

表皮生长因子家族(Epidermal growth factor family)是一组具有与表皮生长因子(Epidermal Growth Factor,EGF)较高同源结构及相似生物学功能的糖蛋白,均为EGF受体的配体,具有调节胚胎细胞生长和分化以及与移动的细胞外基质蛋白相互作用等特点.综述了海胆EGF家族成员的基本生物学特性及其EGF相关蛋白家族的研究进展.     

rh-GH在促进大鼠创面愈合中的作用研究

目的:通过在大鼠背部创面周围局部注射rh-GH(重组人生长激素,Recombinant Human Growth Hormone)来调控创面局部GH(生长激素,Growth Factor)水平,观察GH在创面愈合中的作用,并对其可能机制进行进一步研究。方法:在SD大鼠背部制作创面,创周定期注射不同浓度rh-GH,观察并分析创面愈合速度差异;选取rh-GH的最适浓度进行创周注射并定期取材,以Western-Blot检测创周组织中GH蛋白水平,并以RT-PCR检测创周组织中EGF(表皮生长因子,Epidermal Growth Factor)、FGF(成纤维细胞生长因子,Fibroblast Growth Factor)、VEGF(血管内皮细胞生长因子,Vascular Endothelial Growth Factor)的表达变化。结果:三个注射不同剂量rh-Gh的实验组大鼠创面平均愈合时间由快至慢依次为16.5±1.5天、17.1±2.9天、18.5±1.5天,与注射生理盐水的对照组平均愈合时间21.7±2.3天相比均明显增快,差异有统计学意义(P0.05)。创缘组织中GH的Western-Blot结果显示对照组GH水平在创面形成初期升高,但伤后4天开始GH表达水平即逐渐下降,而rh-GH注射组的GH水平在创面形成后逐渐升高,并维持GH在高表达水平。检测创周组织中EGF、FGF、VEGF的RNA转录水平,PCR结果显示实验组各生长因子的基因转录水平在伤后2天起即明显高于对照组,差异有统计学意义(P0.05)。结论:1.创伤初期创面周围组织中GH表达水平呈现一过性升高然后逐渐下降的过程;2.创面周围注射rh-GH可以提高组织中GH水平,并减少创面愈合时间;3.GH可以提高皮肤组织中EGF、FGF、VEGF水平,间接促进创面上皮化,加快创面愈合。     

嵌合表皮生长因子疫苗E5T-mSEA的设计及抑瘤活性检测

表皮生长因子受体(Epidermal growth factor receptor,EGFR)及其配体在多种肿瘤细胞中高表达,免疫注射表皮生长因子(Epidermal growth factor,EGF)-载体蛋白所产生的抗体能够干扰EGFR与EGF的相互作用,进而抑制肿瘤生长。本实验室设计了EGF和TGFα的嵌合配体E5T,并将具有免疫增强作用的葡萄球菌肠毒素A(Staphylococcal enterotoxin A,SEA)与之融合。融合蛋白在大肠杆菌内表达后,通过金属螯合亲和层析,得到了纯度较高的E5T-mSEA融合蛋白。将E5T-mSEA免疫小鼠,能够产生高滴度的抗体,该抗体能够同时识别EGF和TGFα。将抗E5T-mSEA免疫血清与肿瘤细胞共培养,在1:10的稀释度下能显著抑制EGFR阳性肿瘤细胞的生长,而对EGFR阴性肿瘤细胞293T的生长没有明显影响。     

阿霉素肾病大鼠表皮生长因子及其受体的表达

目的研究阿霉素肾病大鼠肾组织中表皮生长因子(EGF)及其受体EGFR的表达分布以及表达量与尿蛋白之间关系。方法选择第5天、14天、28天作为动态观察的时点,同期设立正常对照。采用荧光定量RT-PCR、免疫组织化学及计算机图像定量分析EGF mRNA以及EGF、EGFR蛋白在肾组织的表达,同时测定24 h尿蛋白定量。WT1和EGFR双重免疫组化确定EGFR在肾小球内确切细胞定位。结果阿霉素注射后第5天,EGFmRNA即较正常增高,28 d明显增高并高于5 d和14 d。正常对照组EGF阳性细胞主要分布于远曲小管和髓袢,阿霉素组EGF还在集合管和近曲小管上表达;EGF阳性表达范围和强度随尿蛋白增加而增加;EGFmRNA表达量以及EGF在肾小管中的表达强度与24 h尿蛋白量呈正相关。肾小管上皮细胞广泛表达EGFR,阿霉素组EGFR在小管表达均高于正常,但组间各时点差异无显著性;随尿蛋白增加EGFR在肾小球内表达逐渐增多。EGFR在肾小球和肾小管中的表达强度均与24 h尿蛋白量呈正相关。WT1和EGFR双重免疫组化显示阿霉素肾病组EGFR可在足突细胞上表达,正常组则无。结论阿霉素肾病大鼠的肾小球脏层上皮有EGFR的表达。EGF/EGFR可能参与了阿霉素肾病的发病过程以及蛋白尿的形成。     

肺泡型细胞内表皮生长因子和转化生长因子α、β_1及其受体基因表达的研究

分离培养成年大鼠的肺泡 型细胞 ,通过斑点杂交、原位杂交和免疫组织化学染色 ,研究肺泡 型细胞内表皮生长因子 (EGF)、转化生长因子 α和 β1 (TGFα、TGFβ1 )及其受体基因的表达。结果显示肺泡 型细胞可表达 EGF、TGFα和TGFβ1 ,也可表达相应的 EGF受体 (EGFR)、TGFβ受体 型和 型 (TβR 、TβR )。表明肺泡 型细胞是合成和分泌 EGF、TGFα和 TGFβ1 的细胞之一 ;细胞凭借其 EGFR、TβR的存在 ,其增殖与分化可能受 EGF、TGFα和 TGFβ1 的旁分泌和自分泌两种途径调控。     

EGFR在晚期肺腺癌患者中的表达及临床意义

目的探讨表皮生长因子受体(EGFR)在晚期肺腺癌患者中的表达及其意义。方法收集60例晚期肺腺癌患者的胸腔积液及活检肺癌组织,采用免疫组化检测EGFR的表达,并探讨其表达与临床病理特征的关系。结果 EGFR在胸腔积液及肺癌组织中的阳性表达率分别为75.0%(45/60)、63.3%(38/60),两者差异无统计学意义(P0.05)。结论 EGFR均高表达于肺腺癌胸腔积液及腺癌组织,且与年龄、性别、吸烟史、分化程度及肿瘤的大小无明显相关,可指导肺腺癌患者的靶向治疗。     

VEGF-D在甲状腺癌组织中的表达和意义

目的:探讨甲状腺癌中血管内皮生长因子-D(Vascular Endothelial Growth Factor,VEGF-D)在甲状腺癌中的表达及意义.方法:免疫组织化学染色方法分别对16例癌周正常组织和56例甲状腺癌组织切片染色,观察癌周正常组织和甲状腺癌组织VEGF-D的表达情况.结果:(1)在甲状腺癌中VEGF-D阳性表达主要见于细胞的胞膜上和胞质中.VEGF-D阳性表达在癌周正常组织和甲状腺癌分别为18.7%和71.4%,两者在统计学上有显著差异.(2)在甲状腺癌中VEGF-D在淋巴结非转移组表达阳性率为60.0%,而转移组表达为83.8%,明显高于非转移组,两者问在统计学上有显著差异.(3)在甲状腺乳头状癌中VEGF-D阳性表达在非转移组50%,淋巴结转移组85.1%,明显高于非转移组,说明VEGF-D在淋巴结转移组比非淋巴结转移组表达显著,VEGF-D的阳性表达与甲状腺癌的淋巴结转移显著相关.结论:(1)在癌周甲状腺组织VEGF-D阳性反应较弱,在甲状腺癌组织VEGF-D阳性反应较强,两者比较有显著性差异.(2)在甲状腺癌中,尤其是甲状腺乳头状癌中,其癌组织中VEGF-D的表达强度增加,与无淋巴结转移的甲状腺癌组织相比,有淋巴结转移的甲状腺癌组织中VEGF-D的表达较强,可作为肿瘤转移的指标之一.     

甲状腺乳头状癌中Survivin,VEGF,EGFR的表达及临床意义分析

目的:探讨甲状腺乳头状癌(PTC)中存活素(Survivin)、血管内皮生长因子(VEGF)、表皮生长因子受体(EGFR)的表达及临床意义。方法:选择2013年4月~2016年4月在我院收治的100例PTC患者的手术标本以及同期100例癌旁正常甲状腺组织为研究对象,采用免疫组化方法检测盒比较Survivin、VEGF、EGFR的表达在PTC及癌旁正常甲状腺组织中的表达及二者的相关性,并分析其Survivin、VEGF、EGFR的表达与PTC患者临床病理特征的相关性。结果:PTC组织中Survivin、VEGF、EGFR阳性表达率均显著高于癌旁正常甲状腺组织,差异具有统计学意义(P0.05);Survivin、VEGF在淋巴结转移患者中的阳性表达率显著高于无淋巴结转移者(P0.05);EGFR在女性PTC患者中的阳性表达率显著高于男性(P0.05)。PTC组织中VEGF和Survivin、EGFR的表达无显著相关性(P0.05),但Survivin和EGFR的表达显著相关(r=0.235,P0.05)。结论:Survivin、VEGF、EGFR在PTC组织中表达上调,Survivin、VEGF与PTC的淋巴结转移有关,Survivin和EGFR在PTC的发生、发展过程中可能存在着协同作用。     

E-cad、EGFR、MMP9 与肺癌转移的关系

目的:探讨原发性非小细胞肺癌(NSCLC)组织中E-钙粘蛋白(E-cadherin,E-cad)、表皮生长因子受体(Epidermal Growth FactorReceptor,EGFR)和基质金属蛋白酶9(matrix metalloproteinase-9,MMP9)的表达与术后复发及转移的关系。方法:选择临床IB期非小细胞肺癌患者的手术切除标本,其中36例于36个月之内发生复发或转移,30例术后无病生存期超过36个月。采用免疫组织化学方法检测组织中E-cad、EGFR、MMP9的表达情况。结果:36例早转移IB期非小细胞肺癌术后患者的手术标本中,E-cad的异常表达率、EGFR及MMP9的阳性表达率,均明显高于30例非早转移IB期非小细胞肺癌术后患者(P<0.05),且在早转移IB期NSCLC中,三者的表达与病理分级、肿瘤大小有关(P<0.05),与病理类型,肿瘤是否浸润胸膜无关(P>0.05)。结论:对早期肺癌术后病人,检测E-cad、EGFR、MMP9的表达,对判断其恶性程度,提示肿瘤的复发及转移倾向大小,决定术后治疗方案有重要意义。     

不同性质甲状腺结节与微血管密度关系的研究

目的:探讨不同性质甲状腺结节与微血管密度关系,提高认识.方法:分别选取甲状腺乳头状癌、甲状腺腺瘤、结节性甲状腺肿及正常甲状腺组织,病理切片行常规HE染色及免疫组化SP染色.在高倍视野(×400)下选取5个血管着色密集区进行计数并取其平均数,MVD值=(n1 +n2+n3+n4+n5)/5.结果:(1)甲状腺乳头状癌、甲状腺腺瘤、结节性甲状腺肿及正常甲状腺组织平均MVD值分别为(65.54±19.21)个/HP、(54.54±11.76)个/HP、(47.85± 10.92)个/HP、(21.82±7.43)个/HP,甲状腺乳头状癌MVD值显著高于甲状腺腺瘤、结节性甲状腺肿及正常甲状腺组织(P＜0.05).甲状腺腺瘤、结节性甲状腺肿MVD值显著高于正常甲状腺组织(P＜0.05).(2)伴有淋巴结转移的甲状腺乳头状癌患者MVD值显著高于不伴有淋巴结转移者(P＜0.05);男性甲状腺乳头状癌患者MVD值显著高于女性患者(P＜0.05);＞40岁及≤40岁甲状腺乳头状癌患者MVD值间无统计学差异(P＞0.05).结论:甲状腺乳头状癌MVD值显著高于甲状腺腺瘤、结节性甲状腺肿及正常甲状腺组织,且伴有淋巴结转移的甲状腺乳头状癌患者MVD值显著高于不伴有淋巴结转移者.     

假基因HMGA1L2在甲状腺肿瘤中的表达

应用RT-PCR技术检测假基因HMGA1L2在50例良、恶性甲状腺病变中HMGA1L2 mRNA的表达。结果显示HMGA1L2 mRNA在12例结节性甲状腺肿、9例甲状腺腺瘤和15例甲状腺乳头状癌中的阳性表达率均为100%, 而在14例甲状腺滤泡癌中的阳性率为35.7%, 与前3者差异有显著性。该研究首次报告了假基因HMGA1L2 mRNA在良、恶性甲状腺病变中的表达, 并且提示其在甲状腺滤泡癌与腺瘤的鉴别诊断中具有潜在的价值。     

Bio-Imaging of Colorectal Cancer Models Using Near Infrared Labeled Epidermal Growth Factor

Novel strategies that target the epidermal growth factor receptor (EGFR) have led to the clinical development of monoclonal antibodies, which treat metastatic colorectal cancer (mCRC) but only subgroups of patients with increased wild type KRAS and EGFR gene copy, respond to these agents. Furthermore, resistance to EGFR blockade inevitably occurred, making future therapy difficult. Novel bio-imaging (BOI) methods may assist in quantization of EGFR in mCRC tissue thus complementing the immunohistochemistry methodology, in guiding the future treatment of these patients. The aim of the present study was to explore the usefulness of near infrared-labeled EGF (EGF-NIR) for bio-imaging of CRC using in vitro and in vivo orthotopic tumor CRC models and ex vivo human CRC tissues. We describe the preparation and characterization of EGF-NIR and investigate binding, using BOI of a panel of CRC cell culture models resembling heterogeneity of human CRC tissues. EGF-NIR was specifically and selectively bound by EGFR expressing CRC cells, the intensity of EGF-NIR signal to background ratio (SBR) reflected EGFR levels, dose-response and time course imaging experiments provided optimal conditions for quantization of EGFR levels by BOI. EGF-NIR imaging of mice with HT-29 orthotopic CRC tumor indicated that EGF-NIR is more slowly cleared from the tumor and the highest SBR between tumor and normal adjacent tissue was achieved two days post-injection. Furthermore, images of dissected tissues demonstrated accumulation of EGF-NIR in the tumor and liver. EGF-NIR specifically and strongly labeled EGFR positive human CRC tissues while adjacent CRC tissue and EGFR negative tissues expressed weak NIR signals. This study emphasizes the use of EGF-NIR for preclinical studies. Combined with other methods, EGF-NIR could provide an additional bio-imaging specific tool in the standardization of measurements of EGFR expression in CRC tissues.     

表皮生长因子受体信号通路在维吾尔族妇女宫颈癌中的表达研究

目的:随着表皮生长因子受体(epidermal growth factor receptor,EGFR)靶点治疗药物在其它肿瘤治疗中的应用,能否在妇科肿瘤中应用并取得疗效,已经得到学者们的重视。但在临床应用之前,必须明确EGFR与妇科肿瘤发生发展的关系及其机制。因此,我们来探讨表皮生长因子受体EGFR信号通路在维吾尔族不同级别宫颈病变组织中的差异表达及其临床意义。方法:应用免疫组织化学方法检测EGFR、P-EGFR、ERK 1/2、P-ERK1/2在108例子宫颈癌,47例CIN,79例正常宫颈组织中的表达,并分析其与临床病理参数的关系。结果:EGFR在子宫颈癌、CIN及正常宫颈组织中的阳性表达率分别是74.10%、66%、27.80%(P0.01);P-EGFR在三组间的阳性表达率分别是55.60%、74.50%、20.30%(P0.01);ERK1/2在三组间的阳性表达率分别是60.10%、76.60%、25.30%(P0.01);P-ERK1/2在三组间的阳性表达率分别是44.40%、66%、24.10%(P0.01),其在宫颈癌中EGFR与与浸润深度、淋巴结转移有关;ERK与肿瘤的临床分期、远处转移有关,而且在宫颈癌中EGFR与P-EGFR、ERK 1/2、P-ERK1/2的表达成正相关(P0.05)。结论:EGFR、P-EGFR、ERK1/2、P-ERK1/2的表达与宫颈癌的发生、发展相关,促进宫颈癌的浸润和转移,抑制EGFR信号通路可能为多靶点联合治疗宫颈癌提供新的方向。     

Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity

The members of the epidermal growth factor (EGF)/ErbB family are prime targets for cancer therapy. However, the therapeutic efficiency of the existing anti-ErbB agents is limited. Thus, identifying new molecules that inactivate the ErbB receptors through novel strategies is an important goal on cancer research. In this study we have developed a shorter form of human EGF (EGFt) with a truncated C-terminal as a novel EGFR inhibitor. EGFt was designed based on the superimposition of the three-dimensional structures of EGF and the Potato Carboxypeptidase Inhibitor (PCI), an EGFR blocker previously described by our group. The peptide was produced in E. coli with a high yield of the correctly folded peptide. EGFt showed specificity and high affinity for EGFR but induced poor EGFR homodimerization and phosphorylation. Interestingly, EGFt promoted EGFR internalization and translocation to the cell nucleus although it did not stimulate the cell growth. In addition, EGFt competed with EGFR native ligands, inhibiting the proliferation of cancer cells. These data indicate that EGFt may be a potential EGFR blocker for cancer therapy. In addition, the lack of EGFR-mediated growth-stimulatory activity makes EGFt an excellent delivery agent to target toxins to tumours over-expressing EGFR.     

乳头状甲状腺癌中线粒体DNA突变的研究

该文探究了线粒体DNA(mtDNA)突变与甲状腺癌的发生发展的相关性,评估了mtDNA拷贝数对甲状腺癌的诊断价值。根据对结节性甲状腺肿、滤泡状甲状腺腺瘤和乳头状甲状腺癌3组病人的mtDNA全基因测序和单倍型分型结果,统计3组病人mtDNA突变率及单倍型的差异,分析乳头状甲状腺癌病人的mtDNA突变率与临床资料的联系,最后通过荧光定量PCR检测3组病人的组织和血液样本中mtDNA的拷贝数。结果显示,乳头状甲状腺癌患者mtDNA的复合体I亚基编码区和tRNA编码区的突变率明显高于结节性甲状腺肿,在乳头状甲状腺癌患者中线粒体单体型M相对于单体型N有更低的淋巴结转移率,荧光定量PCR结果显示,甲状腺腺瘤和甲状腺癌组织中的mtDNA拷贝数明显高于结节性甲状腺肿,而在血液标本中,两者的mtDNA拷贝数均低于结节性甲状腺肿。这些结果表明,mtDNA拷贝数的变化和复合体I亚基编码区的突变可能作为甲状腺癌诊断的生物指标,而线粒体单体型N可能可以作为乳头状甲状腺癌恶性变化的预警指标。     

Expression of CD44 and cyclin D1 in fine needle aspiration cytology of papillary thyroid carcinoma

OBJECTIVE: To compare the expression pattern of CD44 and cyclin D1 immunostaining in fine needle aspiration specimens of papillary carcinoma of the thyroid and nonpapillary lesions. STUDY DESIGN: The study was performed on 80 fine needle aspiration cytologic smears of thyroid lesion retrospectively using monoclonal antibodies and on histologic material from a proportion of cases. RESULTS: Most papillary carcinomas expressed intense cell membrane or diffuse cytoplasmic staining for CD44 (97.8%). Focal immunoreactivity was observed in follicular neoplasms (28.5%) and nodular goiter (4.7%). There was no difference in CD44 immunostaining between follicular carcinoma and adenoma. Cyclin D1 was expressed in the nuclei of most papillary carcinomas (79.2%). Focal nuclear immunoreactivity was noted in nodular goiters (23.5%) and follicular neoplasms (10%). In resected specimens, all papillary carcinomas (19 cases) showed intense membranous or granular CD44 immunoreactivity. Focal cyclin D1 expression was noted in 52.6%. There was no difference in CD44 and cyclin D1 expression between the group of papillary carcinomas with regional lymph node metastasis as compared to those without metastasis. Positive staining for both CD44 and cyclin D1 would strongly favor papillary carcinoma, although further studies on cytologic material are necessary to verify this diagnostic approach. CONCLUSION: Most papillary carcinomas express CD44 and cyclin D1, whereas it is less common in follicular neoplasms and nodular goiter. This may be helpful in diagnostically difficult cases.     

分子生物学法分析青少年甲状腺肿物临床病理及特点

探讨青少年甲状腺肿物的临床病理学特点,甲状腺癌的复发、转移和结节性甲状腺肿复发的可能相关因素。按WHO病理分型标准和国际抗癌联盟(UICC)TNM分期标准回顾性分析青少年甲状腺肿物124例及其中部分甲状腺癌和结节性甲状腺肿的随访资料。124例甲状腺肿物患者男女比例约为1 3,甲状腺癌39例(31.5%),其中乳头状癌35例,滤泡癌3例,髓样癌1例;甲状腺腺瘤59例(47.6%),结节性甲状腺肿11例(8.9%),结节性甲状腺肿伴腺瘤7例(5.6%),甲状腺炎5例(4%),甲状舌管囊肿3例(2.4%)。本组资料显示,青少年甲状腺癌以乳头状癌为主,其复发、转移与组织学亚型为弥漫硬化型及甲状腺包膜和其外软组织受侵状态相关。虽然常见淋巴结转移、肺转移以及局部侵犯周围软组织,但患者总体预后较好。结节性甲状腺肿的复发与病变弥漫位于双叶有关,而与患者性别、年龄和是否伴有乳头样及腺瘤样增生关系不密切。     

Lewisy Promotes Migration of Oral Cancer Cells by Glycosylation of Epidermal Growth Factor Receptor

Aberrant glycosylation changes normal cellular functions and represents a specific hallmark of cancer. Lewis^y (Le^y) carbohydrate upregulation has been reported in a variety of cancers, including oral squamous cell carcinoma (OSCC). A high level of Le^y expression is related to poor prognosis of patients with oral cancer. However, it is unclear how Le^y mediates oral cancer progression. In this study, the role of Le^y in OSCC was explored. Our data showed that Le^y was upregulated in HSC-3 and OC-2 OSCC cell lines. Particularly, glycosylation of epidermal growth factor receptor (EGFR) with Le^y was found in OC-2 cells, and this modification was absent upon inhibition of Le^y synthesis. The absence of Le^y glycosylation of EGFR weakened phosphorylation of AKT and ERK in response to epidermal growth factor (EGF). Additionally, EGF-triggered cell migration was reduced, but cell proliferation was not affected. Le^y modification stabilized EGFR upon ligand activation. Conversely, absence of Le^y glycosylation accelerated EGFR degradation. In summary, these results indicate that increased expression of Le^y in OSCC cells is able to promote cell migration by modifying EGFR which in turn stabilizes EGFR expression and downstream signaling. Targeting Le^y on EGFR could have a potential therapeutic effect on oral cancer.     

血浆HSP60 和TSGF联合检测甲状腺癌的早期诊断价值

目的:究血浆热休克蛋白-60(HSP60)与肿瘤特异性生长因子(TSGF)联合检测对甲状腺癌的早期诊断价值。方法:于2011年1月~2015年11月期间选取254例甲状腺癌患者(定为甲状腺癌组)、156例结节性甲状腺肿患者(结节性甲状腺肿组)和202例健康者(健康组)为研究对象,采用ELISA法检测三组血浆HSP60、TSGF水平,分析其与甲状腺癌病理因素的关系及诊断的敏感度和特异度。结果:甲状腺癌组的血浆HSP60、TSGF水平均显著高于结节性甲状腺肿组以及健康组,且结节性甲状腺肿组高于健康组,差异均具有统计学意义(P0.05)。甲状腺癌患者血浆HSP60、TSGF水平与年龄、性别、临床分期均无相关性(P0.05)。血浆HSP60、TSGF单独诊断甲状腺癌的敏感度和特异度分别为68.75%、81.82%和83.33%、71.88%,两者联合诊断的敏感度和特异度则分别达到了88.89%和86.72%。结论:在甲状腺癌的早期诊断中,采用血浆HSP60和TSGF联合检测的方式可靠性较高,值得推广应用。